123 related articles for article (PubMed ID: 37659196)
1. Novel ProTide prodrugs of 5-fluoro-2'-deoxyuridine for the treatment of liver cancer.
Jiang L; Pan T; Lv Q; Yuan W; Liu X; Qu X; Luo D; Wan S; Cui S
Eur J Med Chem; 2023 Nov; 260():115763. PubMed ID: 37659196
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation.
Shibamoto Y; Tachi Y; Tanabe K; Hatta H; Nishimoto S
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):397-402. PubMed ID: 14751508
[TBL] [Abstract][Full Text] [Related]
3. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma.
Ning Q; Liu YF; Ye PJ; Gao P; Li ZP; Tang SY; He DX; Tang SS; Wei H; Yu CY
ACS Appl Mater Interfaces; 2019 Mar; 11(11):10578-10588. PubMed ID: 30802029
[TBL] [Abstract][Full Text] [Related]
4. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Zhang X; Zhong JL; Liu W; Gao Z; Xue X; Yue P; Wang L; Zhao C; Xu W; Qu X
Cancer Chemother Pharmacol; 2010 May; 66(1):11-9. PubMed ID: 19756602
[TBL] [Abstract][Full Text] [Related]
5. Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
Peng Y; Yu W; Li E; Kang J; Wang Y; Yang Q; Liu B; Zhang J; Li L; Wu J; Jiang J; Wang Q; Chang J
J Med Chem; 2016 Apr; 59(8):3661-70. PubMed ID: 27022837
[TBL] [Abstract][Full Text] [Related]
6. Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.
Patterson AV; Zhang H; Moghaddam A; Bicknell R; Talbot DC; Stratford IJ; Harris AL
Br J Cancer; 1995 Sep; 72(3):669-75. PubMed ID: 7669579
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 5-fluorouracil and 5-fluoro-2'-deoxyuridine as an effector in radiation-activated prodrugs.
Shibamoto Y; Mimasu Y; Tachi Y; Hatta H; Nishimoto S
J Chemother; 2002 Aug; 14(4):390-6. PubMed ID: 12420858
[TBL] [Abstract][Full Text] [Related]
8. Aryloxy Pivaloyloxymethyl Prodrugs as Nucleoside Monophosphate Prodrugs.
Alanazi AS; Miccoli A; Mehellou Y
J Med Chem; 2021 Nov; 64(22):16703-16710. PubMed ID: 34734726
[TBL] [Abstract][Full Text] [Related]
9. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
[TBL] [Abstract][Full Text] [Related]
10. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy.
Qu CY; Zhou M; Chen YW; Chen MM; Shen F; Xu LM
Int J Nanomedicine; 2015; 10():3911-20. PubMed ID: 26089667
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine.
Zhang L; Qi K; Xu J; Xing Y; Wang X; Tong L; He Z; Xu W; Li X; Jiang Y
J Med Chem; 2023 Mar; 66(6):4150-4166. PubMed ID: 36867101
[TBL] [Abstract][Full Text] [Related]
12. Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years.
Sinokrot H; Smerat T; Najjar A; Karaman R
Molecules; 2017 Oct; 22(10):. PubMed ID: 29035325
[No Abstract] [Full Text] [Related]
13. The prodrugs of 5-fluorouracil.
Malet-Martino M; Jolimaitre P; Martino R
Curr Med Chem Anticancer Agents; 2002 Mar; 2(2):267-310. PubMed ID: 12678747
[TBL] [Abstract][Full Text] [Related]
14. Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.
Rango E; D'Antona L; Iovenitti G; Brai A; Mancini A; Zamperini C; Trivisani CI; Marianelli S; Fallacara AL; Molinari A; Cianciusi A; Schenone S; Perrotti N; Dreassi E; Botta M
Eur J Med Chem; 2021 Nov; 223():113653. PubMed ID: 34161866
[TBL] [Abstract][Full Text] [Related]
15. Mutual Prodrugs of 5-Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs.
Ciaffaglione V; Modica MN; Pittalà V; Romeo G; Salerno L; Intagliata S
ChemMedChem; 2021 Dec; 16(23):3496-3512. PubMed ID: 34415107
[TBL] [Abstract][Full Text] [Related]
16. New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
Szymańska-Michalak A; Wawrzyniak D; Framski G; Kujda M; Zgoła P; Stawinski J; Barciszewski J; Boryski J; Kraszewski A
Eur J Med Chem; 2016 Jun; 115():41-52. PubMed ID: 26994842
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
Xia Z; Wiebe LI; Miller GG; Knaus EE
Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
Randolph JT; Li T; Chris Krueger A; Heyman HR; Chen HJ; Bow DAJ; Van Handel C; Peterkin V; Carr RA; Stolarik D; Dekhtyar T; Irvin M; Krishnan P; Wagner R; DeGoey DA
Bioorg Med Chem Lett; 2020 Apr; 30(7):126986. PubMed ID: 32046903
[TBL] [Abstract][Full Text] [Related]
19. The ProTide Prodrug Technology: From the Concept to the Clinic.
Mehellou Y; Rattan HS; Balzarini J
J Med Chem; 2018 Mar; 61(6):2211-2226. PubMed ID: 28792763
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug.
Tobias SC; Borch RF
Mol Pharm; 2004; 1(2):112-6. PubMed ID: 15832507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
